Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Tubular and mucinous breast cancer: results of a cohort of 917 patients.

Roux P, Knight S, Cohen M, Classe JM, Mazouni C, Chauvet MP, Reyal F, Colombo PE, Jouve E, Chopin N, Daraï E, Coutant C, Lambaudie E, Houvenaeghel G.

Tumori. 2019 Feb;105(1):55-62. doi: 10.1177/0300891618811282. Epub 2018 Dec 20.

PMID:
30900967
2.

Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit.

de Nonneville A, Jauffret C, Gonçalves A, Classe JM, Cohen M, Reyal F, Mazouni C, Chauvet MP, Chopin N, Colombo PE, Jouve E, Darai E, Rouzier R, Coutant C, Gimbergues P, Azuar AS, de Lara CT, Lambaudie E, Houvenaeghel G.

Breast Cancer Res Treat. 2019 Feb 13. doi: 10.1007/s10549-019-05160-9. [Epub ahead of print]

PMID:
30759288
3.

Lymph node positivity in different early breast carcinoma phenotypes: a predictive model.

Houvenaeghel G, Lambaudie E, Classe JM, Mazouni C, Giard S, Cohen M, Faure C, Charitansky H, Rouzier R, Daraï E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Martino M, Fraisse J, Dravet F, Chauvet MP, Boher JM.

BMC Cancer. 2019 Jan 10;19(1):45. doi: 10.1186/s12885-018-5227-3.

4.

A gap analysis of opportunities and priorities for breast surgical research.

Gentilini OD, De Boniface J, Classe JM, Peintinger F, Reimer T, Reitsamer R, Rubio I, Smidt M, Kuehn T.

Lancet Oncol. 2019 Jan;20(1):e1. doi: 10.1016/S1470-2045(18)30916-1. No abstract available.

PMID:
30614465
5.

Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer.

Caruana E, Foucher Y, Tessier P, Frenel JS, Classe JM, Dantan E.

Breast Cancer Res Treat. 2019 Apr;174(2):537-542. doi: 10.1007/s10549-018-05107-6. Epub 2019 Jan 2.

PMID:
30603997
6.

Current Status and Future Perspectives of Axillary Management in the Neoadjuvant Setting.

Kühn T, Classe JM, Gentilini OD, Tinterri C, Peintinger F, de Boniface J.

Breast Care (Basel). 2018 Oct;13(5):337-341. doi: 10.1159/000492437. Epub 2018 Sep 26.

PMID:
30498418
7.

Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.

Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, Rouzier R, Faure C, Paillocher N, Chauvet MP, Houvenaeghel G, Gutowski M, De Blay P, Verhaeghe JL, Barranger E, Lefebvre C, Ngo C, Ferron G, Palpacuer C, Campion L.

Breast Cancer Res Treat. 2019 Jan;173(2):343-352. doi: 10.1007/s10549-018-5004-7. Epub 2018 Oct 20.

PMID:
30343457
8.

Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact.

Houvenaeghel G, de Nonneville A, Cohen M, Classe JM, Reyal F, Mazouni C, Chopin N, Martinez A, Daraï E, Coutant C, Colombo PE, Gimbergues P, Chauvet MP, Azuar AS, Rouzier R, de Lara CT, Muracciole X, Agostini A, Gonçalves A, Lambaudie E.

Breast Cancer Res Treat. 2019 Jan;173(1):111-122. doi: 10.1007/s10549-018-4944-2. Epub 2018 Sep 20.

PMID:
30238274
9.

[Clinical practice for morbidly obese endometrial cancer patients: A french multicentric study].

Loaec C, Vaucel E, Darnis E, Lopes P, Selmes G, Jaffre I, Classe JM.

Bull Cancer. 2018 May;105(5):441-449. doi: 10.1016/j.bulcan.2018.02.007. Epub 2018 Apr 20. French.

PMID:
29681402
10.

Sentinel lymph node biopsy validation for large tumors.

Houvenaeghel G, Quilichini O, Cohen M, Reyal F, Classe JM, Mazouni C, Giard S, Carrabin N, Charitansky H, Darai E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon-DE-Lara C, Lambaudie E.

Int J Surg. 2017 Dec;48:275-280. doi: 10.1016/j.ijsu.2017.10.077. Epub 2017 Nov 24.

PMID:
29175020
11.

Prospective Assessment of First-Year Quality of Life After Pelvic Exenteration for Gynecologic Malignancy: A French Multicentric Study.

Martinez A, Filleron T, Rouanet P, Méeus P, Lambaudie E, Classe JM, Foucher F, Narducci F, Gouy S, Guyon F, Marchal F, Jouve E, Colombo PE, Mourregot A, Rivoire M, Chopin N, Houvenaeghel G, Jaffre I, Leveque J, Lavoue V, Leblanc E, Morice P, Stoeckle E, Verheaghe JL, Querleu D, Ferron G.

Ann Surg Oncol. 2018 Feb;25(2):535-541. doi: 10.1245/s10434-017-6120-z. Epub 2017 Nov 20.

PMID:
29159738
12.

Is post-mastectomy radiation therapy contributive in pN0-1mi breast cancer patients? Results of a French multi-centric cohort.

Forissier V, Tallet A, Cohen M, Classe JM, Reyal F, Chopin N, Mazouni C, Gimbergues P, Daraï E, Colombo PE, Azuar P, Lambaudie E, Houvenaeghel G.

Eur J Cancer. 2017 Dec;87:47-57. doi: 10.1016/j.ejca.2017.10.004. Epub 2017 Nov 3.

PMID:
29107861
13.

[Impact of the preservation of the branches of intercostobrachial nerve on the quality of life of patients operated for a breast cancer].

Saleh Z, Salleron J, Baffert S, Paveau A, Classe JM, Marchal F.

Bull Cancer. 2017 Oct;104(10):858-868. doi: 10.1016/j.bulcan.2017.08.002. Epub 2017 Sep 14. French.

PMID:
28917551
14.

Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.

de Nonneville A, Gonçalves A, Zemmour C, Cohen M, Classe JM, Reyal F, Colombo PE, Jouve E, Giard S, Barranger E, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G.

Eur J Cancer. 2017 Oct;84:34-43. doi: 10.1016/j.ejca.2017.06.043. Epub 2017 Aug 4.

PMID:
28780480
15.

Cancer de l’ovaire : prise en charge pluridisciplinaire du cancer de l’ovaire en première ligne: Recommandations Saint-Paul-de-Vence 2016.

Classe JM, Guyon F, Falandry C, Devouassoux-Shisheboran M, Selle F, Joly F.

Bull Cancer. 2017 May;104 Suppl 1:S6-S15. doi: 10.1016/S0007-4551(17)30157-1. French.

PMID:
28625315
16.

Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).

Houvenaeghel G, Lambaudie E, Cohen M, Classe JM, Reyal F, Garbay JR, Giard S, Chopin N, Martinez A, Rouzier R, Daraï E, Colombo PE, Coutant C, Gimbergues P, Azuar P, Villet R, Tunon de Lara C, Barranger E, Sabiani L, Goncalves A.

Breast. 2017 Aug;34:24-33. doi: 10.1016/j.breast.2017.04.008. Epub 2017 May 3.

PMID:
28475932
17.

Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.

de Nonneville A, Gonçalves A, Zemmour C, Classe JM, Cohen M, Lambaudie E, Reyal F, Scherer C, Muracciole X, Colombo PE, Giard S, Rouzier R, Villet R, Chopin N, Darai E, Garbay JR, Gimbergues P, Sabiani L, Coutant C, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G.

Breast Cancer Res Treat. 2017 Apr;162(2):307-316. doi: 10.1007/s10549-017-4136-5. Epub 2017 Feb 2.

PMID:
28155054
18.

Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.

Houvenaeghel G, Sabatier R, Reyal F, Classe JM, Giard S, Charitansky H, Rouzier R, Faure C, Garbay JR, Daraï E, Hudry D, Gimbergues P, Villet R, Lambaudie E.

Br J Cancer. 2016 Oct 25;115(9):1024-1031. doi: 10.1038/bjc.2016.283. Epub 2016 Sep 29.

19.

Upper outer boundaries of the axillary dissection. Result of the SENTIBRAS protocol: Multicentric protocol using axillary reverse mapping in breast cancer patients requiring axillary dissection.

Nos C, Clough KB, Bonnier P, Lasry S, Le Bouedec G, Flipo B, Classe JM, Missana MC, Doridot V, Giard S, Charitansky H, Charles-Nelson A, Bats AS, Ngo C.

Eur J Surg Oncol. 2016 Dec;42(12):1827-1833. doi: 10.1016/j.ejso.2016.07.138. Epub 2016 Aug 26.

PMID:
27769634
20.

Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.

Houvenaeghel G, Boher JM, Reyal F, Cohen M, Garbay JR, Classe JM, Rouzier R, Giard S, Faure C, Charitansky H, Tunon de Lara C, Daraï E, Hudry D, Azuar P, Gimbergues P, Villet R, Sfumato P, Lambaudie E.

Eur J Cancer. 2016 Nov;67:106-118. doi: 10.1016/j.ejca.2016.08.003. Epub 2016 Sep 16.

PMID:
27640137
21.

Breast cancer in young women: Pathologic features and molecular phenotype.

Sabiani L, Houvenaeghel G, Heinemann M, Reyal F, Classe JM, Cohen M, Garbay JR, Giard S, Charitansky H, Chopin N, Rouzier R, Daraï E, Coutant C, Azuar P, Gimbergues P, Villet R, Tunon de Lara C, Lambaudie E.

Breast. 2016 Oct;29:109-16. doi: 10.1016/j.breast.2016.07.007. Epub 2016 Jul 29.

PMID:
27479041
22.

Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.

Kepenekian V, Elias D, Passot G, Mery E, Goere D, Delroeux D, Quenet F, Ferron G, Pezet D, Guilloit JM, Meeus P, Pocard M, Bereder JM, Abboud K, Arvieux C, Brigand C, Marchal F, Classe JM, Lorimier G, De Chaisemartin C, Guyon F, Mariani P, Ortega-Deballon P, Isaac S, Maurice C, Gilly FN, Glehen O; French Network for Rare Peritoneal Malignancies (RENAPE).

Eur J Cancer. 2016 Sep;65:69-79. doi: 10.1016/j.ejca.2016.06.002. Epub 2016 Jul 26.

PMID:
27472649
23.

Evaluation of sentinel lymph node biopsy after previous breast surgery for breast cancer: GATA study.

Renaudeau C, Lefebvre-Lacoeuille C, Campion L, Dravet F, Descamps P, Ferron G, Houvenaeghel G, Giard S, Tunon de Lara C, Dupré PF, Fritel X, Ngô C, Verhaeghe JL, Faure C, Mezzadri M, Damey C, Classe JM.

Breast. 2016 Aug;28:54-9. doi: 10.1016/j.breast.2016.04.006. Epub 2016 May 20.

PMID:
27214241
24.

Evaluation of mastectomy with immediate autologous latissimus dorsi breast reconstruction following neoadjuvant chemotherapy and radiation therapy: A single institution study of 111 cases of invasive breast carcinoma.

Paillocher N, Florczak AS, Richard M, Classe JM, Oger AS, Raro P, Wernert R, Lorimier G.

Eur J Surg Oncol. 2016 Jul;42(7):949-55. doi: 10.1016/j.ejso.2016.03.024. Epub 2016 Apr 25.

PMID:
27134148
25.

Surgical Complexity Impact on Survival After Complete Cytoreductive Surgery for Advanced Ovarian Cancer.

Martinez A, Ngo C, Leblanc E, Gouy S, Luyckx M, Darai E, Classe JM, Guyon F, Pomel C, Ferron G, Filleron T, Querleu D.

Ann Surg Oncol. 2016 Aug;23(8):2515-21. doi: 10.1245/s10434-015-5069-z. Epub 2016 Mar 23.

PMID:
27008588
26.

Survival impact and predictive factors of axillary recurrence after sentinel biopsy.

Houvenaeghel G, Classe JM, Garbay JR, Giard S, Cohen M, Faure C, Charytansky H, Rouzier R, Daraï E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Martino M, Fraisse J, Dravet F, Chauvet MP, Goncalves A, Lambaudie E.

Eur J Cancer. 2016 May;58:73-82. doi: 10.1016/j.ejca.2016.01.019. Epub 2016 Mar 11.

PMID:
26971077
27.

Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?

Vidal F, Guerby P, Luyckx M, Haddad P, Stoeckle E, Morice P, Leblanc E, Lecuru F, Daraï E, Classe JM, Pomel C, Filleron T, Ferron G, Querleu D, Rafii A.

PLoS One. 2016 Jan 28;11(1):e0147787. doi: 10.1371/journal.pone.0147787. eCollection 2016.

28.

Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis.

Derrien A, Gouard S, Maurel C, Gaugler MH, Bruchertseifer F, Morgenstern A, Faivre-Chauvet A, Classe JM, Chérel M.

Front Med (Lausanne). 2015 Dec 21;2:88. doi: 10.3389/fmed.2015.00088. eCollection 2015.

29.

[Perception of pT1a,b pN0 breast tumor prognosis by the French oncology community: Results of the EURISTIC national survey].

Spielmann M, Dalenc F, Pointreau Y, Azria D, Classe JM, Dromain C, Facchini T, Gonçalves A, Liegeois P, Namer M, Pivot X, Vincent-Salomon A.

Bull Cancer. 2016 Feb;103(2):154-63. doi: 10.1016/j.bulcan.2015.10.007. Epub 2015 Dec 2. French.

PMID:
26652718
30.

Which Surgical Attitude to Choose in the Context of Non-Resectability of Ovarian Carcinomatosis: Beyond Gross Residual Disease Considerations.

Vidal F, Al Thani H, Haddad P, Luyckx M, Stoeckle E, Morice P, Leblanc E, Lecuru F, Daraï E, Classe JM, Pomel C, Mahfoud Z, Ferron G, Querleu D, Rafii A.

Ann Surg Oncol. 2016 Feb;23(2):434-42. doi: 10.1245/s10434-015-4890-8. Epub 2015 Nov 5.

PMID:
26542592
31.

Laparoscopic hysterectomy after concurrent radiochemotherapy in locally advanced cervical cancer compared to laparotomy: A multi institutional prospective pilot study of cost, surgical outcome and quality of life.

Baffert S, Alran S, Fourchotte V, Traore MA, Simondi C, Mathevet P, Loustalot C, Binelli C, Jaffre I, Barranger E, Dupre PF, Ferron G, Houvenaeghel G, Leveque J, Descamps P, Body G, Raudrant D, Classe JM.

Eur J Surg Oncol. 2016 Mar;42(3):391-9. doi: 10.1016/j.ejso.2015.09.010. Epub 2015 Oct 27.

32.

[Lobular invasive breast cancer prognostic factors: About 940 patients].

Jauffret C, Houvenaeghel G, Classe JM, Garbay JR, Giard S, Charitansky H, Cohen M, Bélichard C, Faure C, Darai É, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Martino M, Coutant C, Dravet F, Chauvet MP, Chéreau Ewald E, Penault-Llorca F, Goncalves A, Lambaudie É.

Gynecol Obstet Fertil. 2015 Nov;43(11):712-7. doi: 10.1016/j.gyobfe.2015.09.007. Epub 2015 Oct 16. French.

PMID:
26482833
33.

Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey.

Ferron G, Simon L, Guyon F, Glehen O, Goere D, Elias D, Pocard M, Gladieff L, Bereder JM, Brigand C, Classe JM, Guilloit JM, Quenet F, Abboud K, Arvieux C, Bibeau F, De Chaisemartin C, Delroeux D, Durand-Fontanier S, Goasguen N, Gouthi L, Heyd B, Kianmanesh R, Leblanc E, Loi V, Lorimier G, Marchal F, Mariani P, Mariette C, Meeus P, Msika S, Ortega-Deballon P, Paineau J, Pezet D, Piessen G, Pirro N, Pomel C, Porcheron J, Pourcher G, Rat P, Regimbeau JM, Sabbagh C, Thibaudeau E, Torrent JJ, Tougeron D, Tuech JJ, Zinzindohoue F, Lundberg P, Herin F, Villeneuve L; BIG-RENAPE Working Group.

Eur J Surg Oncol. 2015 Oct;41(10):1361-7. doi: 10.1016/j.ejso.2015.07.012. Epub 2015 Jul 29.

PMID:
26263848
34.

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for First Relapse of Ovarian Cancer.

Classe JM, Glehen O, Decullier E, Bereder JM, Msika S, Lorimier G, Abboud K, Meeus P, Ferron G, Quenet F, Marchal F, Gouy S, Pomel C, Pocard M, Guyon F, Bakrin N; French Oncologic and Gynecologic HIPEC Group.

Anticancer Res. 2015 Sep;35(9):4997-5005.

PMID:
26254399
35.

Paired measurement of serum amyloid A (SAA) and paraoxonase 1 (PON1) as useful markers in breast cancer recurrence.

Bobin-Dubigeon C, Lefrançois A, Classe JM, Joalland MP, Bard JM.

Clin Biochem. 2015 Nov;48(16-17):1181-3. doi: 10.1016/j.clinbiochem.2015.07.020. Epub 2015 Jul 17.

PMID:
26188919
36.

[Male breast cancer: prognostic factors, diagnosis and treatment: a multi-institutional survey of 95 cases].

Oger AS, Boukerrou M, Cutuli B, Campion L, Rousseau E, Bussières E, Raro P, Classe JM.

Gynecol Obstet Fertil. 2015 Apr;43(4):290-6. doi: 10.1016/j.gyobfe.2015.02.010. Epub 2015 Mar 26. French.

PMID:
25818033
37.

Occult cancer in specimens of reduction mammaplasty aimed at symmetrization. A multicentric study of 2718 patients.

Sorin T, Fyad JP, Delay E, Rouanet P, Rimareix F, Houpeau JL, Classe JM, Garrido I, Tunon De Lara C, Dauplat J, Bendavid C, Houvenaeghel G, Clough KB, Sarfati I, Leymarie N, Trudel M, Salleron J, Guillemin F, Oldrini G, Brix M, Dolivet G, Simon E, Verhaeghe JL, Marchal F.

Breast. 2015 Jun;24(3):272-7. doi: 10.1016/j.breast.2015.02.033. Epub 2015 Mar 11.

PMID:
25771081
38.

Rates of Neoadjuvant Chemotherapy and Oncoplastic Surgery for Breast Cancer Surgery: A French National Survey.

Clough KB, Acosta-Marín V, Nos C, Alran S, Rouanet P, Garbay JR, Giard S, Verhaeghe JL, Houvenaeghel G, Flipo B, Dauplat J, Dorangeon PH, Classe JM, Rouzier R, Bonnier P.

Ann Surg Oncol. 2015 Oct;22(11):3504-11. doi: 10.1245/s10434-015-4378-6. Epub 2015 Feb 10.

PMID:
25665949
39.

[Prophylactic surgery in patients mutated BRCA or high risk: retrospective study of 61 patients in the ICO].

Oger AS, Classe JM, Ingster O, Morin-Meschin ME, Sauterey B, Lorimier G, Wernert R, Paillocher N, Raro P.

Ann Chir Plast Esthet. 2015 Feb;60(1):19-25. doi: 10.1016/j.anplas.2014.10.001. Epub 2014 Nov 18. French.

PMID:
25453188
40.

Eligibility criteria for intraoperative radiotherapy for breast cancer: study employing 12,025 patients treated in two cohorts.

Ziouèche-Mottet A, Houvenaeghel G, Classe JM, Garbay JR, Giard S, Charitansky H, Cohen M, Belichard C, Faure C, Chéreau Ewald E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Tallet A, Bannier M, Minsat M, Lambaudie E, Resbeut M.

BMC Cancer. 2014 Nov 24;14:868. doi: 10.1186/1471-2407-14-868.

41.

[How to surgery for advanced ovarian serous cancers?].

Lécuru F, Classe JM, Collinet P, Daraï E, Ferron G, Golfier F, Gouy S, Guyon F, Narducci F, Pomel C, Rafii A, Rouzier R, Pujade-Lauraine E.

J Gynecol Obstet Biol Reprod (Paris). 2014 Oct;43(8):557-8. doi: 10.1016/j.jgyn.2014.07.015. Epub 2014 Sep 2. French. No abstract available.

42.

Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

Bakrin N, Classe JM, Pomel C, Gouy S, Chene G, Glehen O.

J Visc Surg. 2014 Oct;151(5):347-53. doi: 10.1016/j.jviscsurg.2014.07.005. Epub 2014 Aug 29. Review.

PMID:
25168575
43.

Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: a French sentinel node multicenter cohort study.

Houvenaeghel G, Classe JM, Garbay JR, Giard S, Cohen M, Faure C, Hélène C, Belichard C, Uzan S, Hudry D, Azuar P, Villet R, Penault Llorca F, Tunon de Lara C, Goncalves A, Esterni B; et al.

Breast. 2014 Oct;23(5):561-6. doi: 10.1016/j.breast.2014.04.004. Epub 2014 May 27.

PMID:
24874284
44.

Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study.

Le Brun JF, Campion L, Berton-Rigaud D, Lorimier G, Marchal F, Ferron G, Oger AS, Dravet F, Jaffre I, Classe JM.

Ann Surg Oncol. 2014 Oct;21(11):3621-7. doi: 10.1245/s10434-014-3693-7. Epub 2014 May 13.

PMID:
24819120
45.

CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg.

Ayyoub M, Pignon P, Classe JM, Odunsi K, Valmori D.

Cancer Immunol Res. 2013 Nov;1(5):303-8. doi: 10.1158/2326-6066.CIR-13-0062-T. Epub 2013 Aug 19.

46.

An original approach was used to better evaluate the capacity of a prognostic marker using published survival curves.

Dantan E, Combescure C, Lorent M, Ashton-Chess J, Daguin P, Classe JM, Giral M, Foucher Y.

J Clin Epidemiol. 2014 Apr;67(4):441-8. doi: 10.1016/j.jclinepi.2013.10.022.

PMID:
24581297
47.

Incidence of occult contralateral carcinomas of the breast following mastoplasty aimed at symmetrization.

Sorin T, Fyad JP, Pujo J, Colson T, Bordes V, Leroux A, Marchal F, Brix M, Simon E, Verhaeghe JL, Classe JM, Dolivet G.

Ann Chir Plast Esthet. 2014 Apr;59(2):e21-8. doi: 10.1016/j.anplas.2013.12.007. Epub 2014 Feb 13.

PMID:
24530086
48.

Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study.

Houvenaeghel G, Goncalves A, Classe JM, Garbay JR, Giard S, Charytensky H, Cohen M, Belichard C, Faure C, Uzan S, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Martino M, Lambaudie E, Coutant C, Dravet F, Chauvet MP, Chéreau Ewald E, Penault-Llorca F, Esterni B.

Ann Oncol. 2014 Mar;25(3):623-8. doi: 10.1093/annonc/mdt532. Epub 2014 Jan 7.

49.

Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.

Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, Abboud K, Meeus P, Ferron G, Quenet F, Marchal F, Gouy S, Morice P, Pomel C, Pocard M, Guyon F, Porcheron J, Glehen O; FROGHI (FRench Oncologic and Gynecologic HIPEC) Group.

Eur J Surg Oncol. 2013 Dec;39(12):1435-43. doi: 10.1016/j.ejso.2013.09.030. Epub 2013 Oct 17.

PMID:
24209430
50.

[Diagnostic laparoscopy in gynecological cancer, prophylactic oophorectomy: feasibility study on 22 cases].

Le Brun JF, Dravet F, Campion L, Classe JM.

J Gynecol Obstet Biol Reprod (Paris). 2014 Mar;43(3):229-34. doi: 10.1016/j.jgyn.2013.08.010. Epub 2013 Oct 3. French.

Supplemental Content

Loading ...
Support Center